Biography and Research Information
OverviewAI-generated summary
Bhavesh Mohan Lal's research focuses on hematologic malignancies, particularly multiple myeloma, and the application of advanced therapies. His work includes investigating the real-world outcomes of treatments such as talquetamab in relapsed refractory multiple myeloma and the influence of prior exposure to belantamab mafodotin on outcomes with idecabtagene vicleucel. Lal also contributes to the understanding of myelodysplastic syndromes, exploring their pathogenic mechanisms and therapeutic advances. In addition to oncology, his publications address the safety and efficacy of CAR-T cell therapy in autoimmune diseases and systematic reviews on topics including autoimmune encephalitis associated with COVID-19 and its vaccines. He has also published on ultrasonography for obstructive sleep apnea and pneumothorax in COVID-19 patients. Lal's scholarly metrics include an h-index of 4 with 35 total publications and 72 citations.
Metrics
- h-index: 5
- Publications: 35
- Citations: 84
Selected Publications
-
New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Critical platelet shortages and a single Institution's experience with split platelet transfusions: Can you get by with just half a unit? (2025)
-
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
-
Incidentally Detected Pulmonary Carcinoid Tumorlet With Coexisting Carcinoid Tumorlet in the Mediastinal Lymph Node in a Patient With Lung Cancer (2025)
-
International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings (2025)
-
Prognostic significance of neutrophil-to-lymphocyte ratio in small cell lung cancer in the era of immunotherapy. (2025)
-
Impact of demographic and socioeconomic factors on survival outcomes in patients with Waldenstrom macroglobulinemia: A SEER database analysis from 2000-2021. (2025)
-
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)
-
Incidence and impact of incidental pulmonary embolism in solid cancer patients. (2025)
-
MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma. (2025)
-
NSCLC in the immunotherapy era: Trends in survival and disparities across demographic and socioeconomic groups. (2025)
-
Patterns of mortality in lung cancer patients in the era of immunotherapy and targeted therapy: A single-center, retrospective, observational study. (2025)
-
Addressing practical challenges with bispecific antibody therapy in multiple myeloma (2025)
-
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience (2025)
Collaboration Network
Top Collaborators
Samer Al Hadidi
University of Arkansas for Medical Sciences
9 shared publications
In database
- Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review
- Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
- Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Showing 5 of 9 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
7 shared publications
In database
- Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
- Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
Showing 5 of 7 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
7 shared publications
In database
- Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
- Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
Showing 5 of 7 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
7 shared publications
In database
- Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
- Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Showing 5 of 7 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
6 shared publications
In database
- Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
- Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
Showing 5 of 6 shared publications
Toshali Pandey
University of Arkansas for Medical Sciences
6 shared publications
In database
- Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
- Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
- MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma.
- Abstract 4358782: Redefining Cardiotoxicity Surveillance in Targeted Immunotherapy: Cytokine Release Syndrome as a High-Yield Trigger for Detecting Cancer Therapy-Related Cardiac Dysfunction After CAR-T Therapy
- AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics
Showing 5 of 6 shared publications
Marah Alzubi
5 shared publications
- Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
- Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
- Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
- Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma
Jawad Alrawabdeh
University of Jordan (JO)
5 shared publications
- Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
- Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
- Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
- Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma
Muthu Sendhil Kumaran
University of Arkansas for Medical Sciences (US)
5 shared publications
- Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances
- Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy
- Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting
- Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study.
- Critical platelet shortages and a single Institution's experience with split platelet transfusions: Can you get by with just half a unit?
Animesh Ray
All India Institute of Medical Sciences (IN)
4 shared publications
- Pneumothorax and pneumomediastinum in patients with COVID-19: A retrospective study from tertiary care institute in India
- Ultrasonography of the neck in patients with obstructive sleep apnea
- Polymyxin B-induced Bartter syndrome
- Development of a Body Mass Index-Independent (SWET) Score to Predict Moderate or Severe Obstructive Sleep Apnea in Indian Population
Sanjeev Sinha
All India Institute of Medical Sciences (IN)
4 shared publications
- Ultrasonography of the neck in patients with obstructive sleep apnea
- Study of the upper airway anatomy using magnetic resonance imaging in Indian obese patients with obstructive sleep apnea – A pilot study
- Survival of Children Living with HIV/AIDS: A Multicentric Study from India
- Development of a Body Mass Index-Independent (SWET) Score to Predict Moderate or Severe Obstructive Sleep Apnea in Indian Population
Eric R. Siegel
University of Arkansas for Medical Sciences
4 shared publications
In database
- Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
- Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
- Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience
Mamatha Gaddam
University of Arkansas for Medical Sciences
4 shared publications
In database
- Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances
- Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy
- Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting
- Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study.
Ankur Varma
University of Arkansas for Medical Sciences
4 shared publications
In database
- Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances
- Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy
- Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting
- Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study.
Surabhi Vyas
All India Institute of Medical Sciences (IN)
3 shared publications
- Pneumothorax and pneumomediastinum in patients with COVID-19: A retrospective study from tertiary care institute in India
- Ultrasonography of the neck in patients with obstructive sleep apnea
- Study of the upper airway anatomy using magnetic resonance imaging in Indian obese patients with obstructive sleep apnea – A pilot study
Similar Researchers
Based on overlapping research topics
Naveen Yarlagadda
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Syed Mujtaba Ali Naqvi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Munawar Hussain .
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Cancer Treatment and Pharmacology
Samer Al Hadidi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Cancer Treatment and Pharmacology
Eric R. Siegel
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Cancer Treatment and Pharmacology
Jaskirat Sethi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Cancer Treatment and Pharmacology